Ex­pand­ing its pre­clin­i­cal at­tack on Duchenne MD, Sarep­ta grabs a li­cense for Duke's CRISPR tech

Sarep­ta $SRPT an­nounced this morn­ing that it’s team­ing up with Duke Uni­ver­si­ty to ex­plore new CRISPR-based meth­ods in the hunt for an ef­fec­tive Duchenne mus­cu­lar …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER